EAHP represents over 29,000 hospital pharmacists across 36 member countries. EAHP represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. This is achieved through science, research, education, practice, as well as sharing best-practice and responsibility with other healthcare professionals.
The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
The EAHP staff supports the Board in executing EAHP’s mission. The Staff assists in financial management, events organisations, policy activities and all EAHP projects. The EAHP staff works closely with EAHP’s members and ensures the effective communication all relevant stakeholders.
The first member countries were Belgium, Britain, Denmark, France, the Federal Republic of Germany and The Netherlands in 1972. EAHP has now 36 EAHP members and 2 Associate Members. EAHP is open to countries members of the Council of Europe and since 2022 to organisations representing the interests of hospital pharmacists from outside the Council of Europe (Associate Membership)
EAHP’s structure is also composed by different standing committes: EAHP Scientific Committee, EAHP Education Executive Committee and the EAHP CTF Steering Committee.
At EAHP, we are committed to transparency in our governance, ethical standards, and funding practices. This section provides open access to our foundational documents, including the EAHP Statutes, Code of Conduct, and Funding Sources. By sharing these resources, we aim to uphold accountability and foster trust with our members, partners, and the public.
Keep up with all EAHP’s events and webinars. Contact the team at info@eahp.eu should you have any questions about upcoming events or activities.
Here you can find all upcoming events organised by EAHP and by all its members and associate members. Do not hesitate to contact the events team at events@eahp.eu should you have any questions about the organisation of these events.
Hospital pharmacists conduct a critical role in the care of patients in hospitals. Learn more about what they do here and in all the pages under Hospital Pharmacy practice and Policy.
Self-Assessment
SILCC
Closed SIGs
EAHP brings together experts from many areas of hospital pharmacy practice providing and highlighting good local sustainable practices as that can be up-scaled and shared with other countries. The EAHP Working Group on Sustainability has the aim of reducing the environmental burden of the hospital pharmacy services.
The European Association of Hospital Pharmacists (EAHP), and its 36 member country platforms are creating a Common Training Framework for the hospital pharmacy education in Europe. The goal of this project is to allow the free movement of hospital pharmacists within the European Union.
The European Association of Hospital Pharmacists (EAHP) and the European Society of Clinical Pharmacy (ESCP) have collaboratively developed the Oath to Society. The Oath to Society is all encompassing and acts as a contract for excellence in providing compassionate patient care, working as part of the healthcare team and advancing the pharmacy profession, and showcasing how clinical and hospital pharmacists work every day
A day created to highlight the importance and to celebrate the work done by hospital pharmacies. This day celebrates all hospital pharmacy teams.
Catch up with EAHP’s press releases
Find all EAHP relevant publication like the EAHP Surveys, annual reports and the history books.
The European Journal of Hospital Pharmacy (EJHP) is the only official journal of the European Association of Hospital Pharmacists (EAHP) and is committed to advancing the science, practice and profession of hospital pharmacy. As the premier communication platform for hospital pharmacists worldwide, EJHP is a major source for continuing education as well as updates on advances in the practice and standard of pharmaceutical care for patients.
When EAHP and Hospital pharmacists appear in the news.
EAHP publishes a monthly EU monitor with updates about the latest EAHP initiatives and information relevant for the hospital pharmacy profession.
Sponsor Channel
The Sponsor Channel is designed to maximise visibility and engagement, allowing sponsors to connect with the hospital pharmacy community and partners in a dynamic and interactive environment. From product demonstrations to networking sessions, the Sponsor Channel offers a range of opportunities for sponsors to showcase their offerings and generate leads in the new EAHP Website.
The EAHP EU Monitor is a regular round up of news relevant to hospital pharmacy in Europe.
EHMA and EAHP are conducting a survey targeting hospital pharmacists and pharmacy managers, focusing on the collection and sharing of data related to medication demand and stocks. The survey aims to identify how hospitals currently gather and share data on medication stock and demand, identify any barriers to collecting information on medicines stocks, and explore the workload implications and digitalisation requirements for hospital pharmacy workflows in relation to data collection. The survey will remain open for three months. The results will be collected and published in a briefing paper that will be shared with EU policymakers and the European Medicines Agency.
Find the survey HERE.
The European Association of Hospital Pharmacists (EAHP) and SEFH (Spanish Society of Hospital Pharmacists – Sociedad Española de Farmacia Hospitalaria) are holding the 5th EAHP Synergy Certification Course on the 23rd and 24th of November, taking place in Alicante, Spain. Those who decide to join at short notice can still register for the event until November 11.
During this EAHP-SEFH Synergy Certification Course, attendees will be able to acquire the latest knowledge around the theme “Addressing outpatient pharmaceutical care needs from the perspective of hospital pharmacy”. A variety of topics will be addressed in the Synergy Certification Course, including strategies developed by the different European countries for outpatient pharmaceutical attention improvement,development and establishment of healthcare stratification, best practices in patients with specific disease patterns (oncohematology, immune-mediated, neurodegenerative diseases, viral pathologies, pneumology, etc.), hospital pharmacy integration strategies in multidisciplinary teams of outpatient assistance, results of pharmaceutical care technology support initiatives in Spain, and agreement on the next steps for the expansion of the ground-breaking strategies in Spain and Europe.
You can find the full programme HERE, and registration can be done by clicking HERE.
The European Commission has published a communication to address critical medicine shortages in Europe. Together with EMA, they will launch a European Voluntary Solidarity Mechanism for medicines in October 2023. They will establish a European Union list of critical medicines by the end of 2023 and analyse selected medicines’ supply chains by April 2024. Furthermore, they will aim for a Joint Action in 2024, which allows Member states to use regulatory exemptions to allow medicines to reach patients promptly, including extending the shelf-life and authorising alternatives. In addition, the Commission aims to publish an EU guidance on procuring medicines by early 2024 and opt for a joint procurement for antibiotics and respiratory virus treatments next winter. A Critical Medicines Alliance will be launched by early 2024 to enhance collaboration, coordinate EU-level public procurement, diversify global supply chains, and streamline funding. Lastly, a unified strategy for medicines stockpiling will be developed with Member States by the first half of 2024.
Learn more about it HERE.
The Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) of the European Medicines Agency (EMA) is developing a European Voluntary Solidarity Mechanism for medicines shortages together with the European Commission. This Mechanism allows a Member State that faces a critical shortage to request assistance from other Member States in obtaining medicine stocks. The Mechanism has strict conditions and should only be used as a last resort. More details on the Solidarity Mechanism can be found in the MSSG toolkit published by EMA.
Learn more about it HERE.
On the 18th of November, the European Antibiotic Awareness Day (EAAD) will take place, a campaign initiated by the European Centre for Disease Prevention and Control (ECDC), which is organised in partnership with the World Health Organisation (WHO) AMR Awareness week, from 18 to 24th of November. This year’s focus of the EAAD will be on the Council’s Recommendation on stepping up EU actions to combat antimicrobial resistance in a One Health approach. Published in June 2023, this recommendation consists of EU strategies to combat antimicrobial resistance up to 2030 and stresses the importance of combined efforts in addressing AMR.
Learn more about it HERE.
An efficient transfer of medication history is crucial for patient safety. A recent article published in the European Journal of Hospital Pharmacy (EJHP) aimed to reduce the time used for medication reconciliation (MR) in the emergency department without compromising the quality of the MR. By restructuring the patient interview (using prescription data-based probing questions and a condensed checklist) and making documentation more concise, the time spent on MR was reduced by 34%. At the same time, the effectiveness in identifying medication discrepancies remained uncompromised. The proportion of patients with at least one identified discrepancy was similar between the revised and original methods (81% vs 79%), as was the average number of discrepancies per patient (1.9). This shows that it is possible to speed up the MR process without compromising its effectiveness in identifying medication discrepancies.
Read the article HERE.
European Commission: risks of Melanoma and prevention measures related to sunbeds
In the area of prevention, the Cancer Plan announced that the Commission would explore measures on exposure to ultraviolet radiation, including from sunbeds, which increases the risk of melanoma, the most serious form of skin cancer. The call for evidence on the risks of UV-light exposure through sunbeds and how to prevent it is open to the 19th of November.
Contribute HERE.
EMA Consultation: reflection paper on the use of artificial intelligence in the lifecycle of medicines
EMA launched a draft reflection paper outlining the current thinking on the use of artificial intelligence (AI) to support the safe and effective development, regulation and use of human and veterinary medicines. The document reflects on principles relevant to the application of AI and machine learning (ML) at any step of a medicine’s lifecycle, from drug discovery to the post-authorisation setting. All interested parties are invited to comment on the consultation. The public consultation is open until 31 December 2023.
Contribute HERE
EMA Consultation: guideline on clinical investigational of medicinal products in the treatment of depression
EMA launched a draft “Guideline on clinical investigation of medicinal products in the treatment of depression”. The document recognises that the emergence of new antidepressants with rapid onset of effect and the repurposing of psychedelics require separate design strategies. It goes on to address key issues for the development of psychedelic-assisted psychotherapy in the field of major depressive disorder. The public consultation is open until 31 March 2024.
Contribute HERE
EFCCA Patient Preference Survey
The European Federation of Chron’s & Ulcerative Colitis Associations (EFCCA) together with the University of Leuven launched the “Patient Preference Survey”. It aims to find out which aspects, factors, and characteristics are important for patients when choosing a treatment for inflammatory bowel disease. The survey has been translated into several languages.
Contribute HERE
